---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-082341"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2026-07-10T01:06:20+00:00"
generated_at: "2026-07-10T10:05:25.843307+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio completes enrollment of 850 patients in pivotal Phase 3 AD trial of buntanetap

## Summary
- Enrolled 850 pTau217-confirmed early AD patients across 83 US sites, exceeding original projections.
- Symptomatic top-line data expected Q1 2027; disease-modifying data expected Q1 2028.
- Company plans two NDA submissions to FDA after each respective data readout.
- Trial is randomized, placebo-controlled, double-blind with daily oral buntanetap 30mg.
- Last patient completes 6-month treatment in January 2027; study on track.

## SEC filing metadata
- accession: 0001104659-26-082341
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2026-07-10T01:06:20+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465926082341/0001104659-26-082341-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465926082341/tm2620172d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-082341
- JSON: https://secwatch.observer/filing/0001104659-26-082341.json
- Plain text: https://secwatch.observer/filing/0001104659-26-082341.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.